Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Allergy and Clinical Immunology

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jaci.2013.11.007PMID 24361082PMCID PMC3960331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term follow-up of oral immunotherapy for cow's milk allergy.

  2013cited by this paper
• Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens.

  2013cited by this paper
• Oral immunotherapy for treatment of egg allergy in children.

  2012cited by this paper
• The safety and efficacy of sublingual and oral immunotherapy for milk allergy.

  2012cited by this paper
• Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy.

  2012cited by this paper
• Evidence of pathway‐specific basophil anergy induced by peanut oral immunotherapy in peanut‐allergic children

  2012cited by this paper
• The natural history of persistent peanut allergy.

  2012cited by this paper
• SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.

  2012cited by this paper
• Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.

  2011cited by this paper
• A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.

  2011cited by this paper
• Forecast for food allergen immunotherapy: partly desensitized or a chance of cure?

  2010cited by this paper
• Oral peanut immunotherapy in children with peanut anaphylaxis.

  2010cited by this paper
• Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance.

  2010cited by this paper
• Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report.

  2010cited by this paper
• Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel.

  2010cited by this paper
• IgE‐mediated facilitated antigen presentation underlies higher immune responses in peanut allergy

  2010cited by this paper
• Food Allergy Among Children in the United States

  2009cited by this paper
• Impact of peanut allergy on quality of life, stress and anxiety in the family

  2009cited by this paper
• Clinical efficacy and immune regulation with peanut oral immunotherapy.

  2009cited by this paper
• Time course of serum inhibitory activity for facilitated allergen–IgE binding during bee venom immunotherapy in children

  2009cited by this paper
• A double‐blind placebo‐controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation

  2008cited by this paper
• A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy.

  2008cited by this paper
• Egg oral immunotherapy in nonanaphylactic children with egg allergy.

  2007cited by this paper
• Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction

  2007cited by this paper
• Further fatalities caused by anaphylactic reactions to food, 2001-2006.

  2007cited by this paper
• The natural history of peanut allergy: Extending our knowledge beyond childhood.

  2007cited by this paper
• The impact of food allergy on the daily activities of children and their families.

  2006cited by this paper
• Outcomes of allergy to insect stings in children, with and without venom immunotherapy.

  2004cited by this paper
• The impact of childhood food allergy on quality of life.

  2001cited by this paper
• Fatalities due to anaphylactic reactions to foods.

  2001cited by this paper
• The natural history of peanut allergy.

  2001cited by this paper
• Allergen immunotherapy: does it work and, if so, how and for how long?

  2000cited by this paper

• Mechanisms of IgE-mediated food allergy and the role of allergen-specific B cells.

  2026cites this paper
• Eosinophilic Esophagitis Incidence during Single and Multiple Food Oral Immunotherapy.

  2026cites this paper
• Oral Immunotherapy-Induced Changes in IgE, IgG, and IgA: A Review of Antibody Isotype Shifts and Their Clinical Relevance in Food Allergy

  2026cites this paper
• Modulating the Allergen-Specific Immune Response to Achieve Remission of Food Allergy Through Oral Immunotherapy.

  2026cites this paper
• Progress in allergen immunotherapy via advanced transdermal delivery routes.

  2026cites this paper
• Induction of tolerance to food allergens—Younger is better

  2025cites this paper
• État des lieux des approches fonctionnelles in vitro pour l’analyse des réactions d’hypersensibilité de type I et IV

  2025cites this paper
• The Etiology of IgE-Mediated Food Allergy: Potential Therapeutics and Challenges

  2025influential citation
• Association of bile acids, amino acids, and glycerophospholipid metabolites with food-allergic outcomes in children on peanut oral immunotherapy

  2025cites this paper
• Advances in Food Allergy Immunotherapy: Current Strategies and Role of Antibodies Isotypes

  2025cites this paper
• Probiotic oral immunotherapy for egg and milk allergy induces sustained unresponsiveness

  2025cites this paper
• Impact of participant baseline factors on exposure-adjusted incidence of treatment-related adverse events during peanut oral immunotherapy.

  2025cites this paper
• Safety Profile of Probiotics as an Adjuvant to Oral Immunotherapy for Food Allergies: A Meta Analysis of Randomized Controlled Trials.

  2025cites this paper
• Peanut Component-Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1-4-Year-Old Children.

  2025cites this paper
• Orale Hyposensibilisierung ist auch bei Kindern eine Option

  2025cites this paper
• Peanut Oral Immunotherapy in Children with High-Threshold Peanut Allergy.

  2025cites this paper
• Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons

  2025cites this paper
• Engineered strategies for the allergic disease therapy

  2025cites this paper
• Epitope‐Specific Antibodies in Allergic Disease and Clinical Tolerance

  2025cites this paper
• The ethics of food allergy

  2025cites this paper
• Elucidation of Desensitization Mechanisms Induced by Oral Immunotherapy in a Rat Model of Ovalbumin Allergy

  2025cites this paper
• Understanding the Variability of Peanut‐Oral Immunotherapy Responses by Multi‐Omics Profiling of Immune Cells

  2025cites this paper
• Scientific developments in understanding food allergy prevention, diagnosis, and treatment

  2025cites this paper
• The Relationship Between Asthma and Food Allergies in Children

  2024cites this paper
• Safety of oral immunotherapy for cashew nut and peanut allergy in children - a retrospective single-centre study.

  2024cites this paper
• Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy.

  2024cites this paper
• The function of antibodies

  2024cites this paper
• WALKING BACKWARDS: REFLECTING ON THE VALUE OF MENTORS.

  2024cites this paper
• Maternal influences on offspring food allergy

  2024cites this paper
• Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase II Study

  2024cites this paper
• The role of intestinal bacteria in promoting tolerance to food.

  2024cites this paper
• Allergie à l’arachide chez l’enfant

  2024cites this paper
• Oral Immunotherapy: An Overview.

  2024cites this paper
• Atopic Dermatitis and IgE-Mediated Food Allergy: Common Biologic Targets for Therapy and Prevention.

  2024cites this paper
• Role of allergen immunotherapy and biologics in allergic diseases.

  2024cites this paper
• Low-dose oral immunotherapy in immunoglobulin E-mediated food allergies

  2024cites this paper
• Design of an Ara h 2 hypoallergen from conformational epitopes

  2024cites this paper
• A Review of Shared Decision-Making, Published Protocols, and Post-desensitization Strategies in Oral Immunotherapy (OIT)

  2024cites this paper
• Development of a Mass Spectrometry-Based Method for Quantification of Total Cashew Protein in Roasting Oil.

  2024cites this paper
• Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways

  2024cites this paper
• Efficacy of biological agents combined with oral immunotherapy (OIT) for food allergy: a protocol for a systematic review and meta-analysis

  2024cites this paper
• Optimising the management of peanut allergy by targeting immune plasticity

  2024cites this paper
• Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years

  2024cites this paper
• Food Allergen Immunotherapy in the Treatment of Patients with IgE-Mediated Food Allergy

  2024cites this paper
• Treatment of food allergy: Immunotherapy, omalizumab, or both.

  2024cites this paper
• Immunotherapy for food allergy: current proposals to improve safety and efficacy

  2024cites this paper
• Whence and wherefore IgE?

  2024cites this paper
• Allergen‐Encapsulating Nanoparticles Reprogram Pathogenic Allergen‐Specific Th2 Cells to Suppress Food Allergy

  2024cites this paper
• EAACI Molecular Allergology User's Guide 2.0

  2023cites this paper
• Allergen immunotherapy: progress and future outlook

  2023cites this paper
• Oral Immunotherapy in Food Allergy: Where Are We Now?

  2023cites this paper
• Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation

  2023cites this paper
• Jak out of the box -targeting BTK, siglec-8, & Jak1 in food allergy.

  2023cites this paper
• Dose and route of administration determine the efficacy of prophylactic immunotherapy for peanut allergy in a Brown Norway rat model

  2023cites this paper
• Targeting type 2 immunity and the future of food allergy treatment

  2023cites this paper
• Food Oral Immunotherapy: A Survey Amongst United States Practicing Allergists Conducted as a AAAAI Leadership Institute Project and Work Group Report.

  2023cites this paper
• Oral Immunotherapy: An Overview.

  2023cites this paper
• [Treatment for living with food allergy].

  2023cites this paper
• [Food desensitization].

  2023cites this paper
• Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy

  2023cites this paper
• Peanut Allergy and Component-Resolved Diagnostics Possibilities—What Are the Benefits?

  2023cites this paper
• Gut microbiota and fecal metabolites in sustained unresponsiveness by oral immunotherapy in school-age children with cow's milk allergy.

  2023cites this paper
• Oral immunotherapy as a curative treatment for food‐allergic preschool children: Current evidence and potential underlying mechanisms

  2023cites this paper
• New Approaches to Food Allergy Immunotherapy.

  2023cites this paper
• Engineering nanoparticle therapeutics for food allergy.

  2023cites this paper
• Preclinical evaluation of alternatives to oral immunotherapy for food allergies

  2023cites this paper
• Update on oral and epicutaneous immunotherapy for children with food allergy

  2023cites this paper
• Mechanisms of desensitization with oral immunotherapy and epicutaneous immunotherapy

  2023cites this paper
• Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI): protocol for a phase 2a randomized controlled trial

  2023influential citation
• Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy

  2023cites this paper
• Endpoints and outcomes following immunotherapy for food allergy: What is meaningful for patients?

  2023cites this paper
• Optimal period for achieving sustained unresponsiveness in peanut oral immunotherapy

  2023cites this paper
• Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.

  2022cites this paper
• Immunotherapy Effectiveness in Treating Peanut Hypersensitivity: A Systemic Review

  2022influential citation
• Phase 2, randomized multi oral immunotherapy with omalizumab ‘real life’ study

  2022cites this paper
• Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.

  2022cites this paper
• The Road Toward Transformative Treatments for Food Allergy

  2022cites this paper
• Mechanisms and biomarkers of successful allergen-specific immunotherapy

  2022cites this paper
• CD8+ T cell differentiation status correlates with the feasibility of sustained unresponsiveness following oral immunotherapy

  2022cites this paper
• Allergen immunotherapy for food allergy: Evidence and outlook

  2022cites this paper
• Biomarkers and mechanisms of tolerance induction in food allergic patients drive new therapeutic approaches

  2022influential citation
• Allergen immunotherapy: past, present and future

  2022cites this paper
• Transitioning peanut oral immunotherapy to clinical practice

  2022cites this paper
• Biomarkers in oral immunotherapy

  2022cites this paper
• Food Allergy and Gastrointestinal Syndromes

  2022cites this paper
• Measuring the Impact of Food Immunotherapy on Health-Related Quality of Life in Clinical Trials

  2022cites this paper
• Approaches to maintenance dosing during oral immunotherapy

  2022cites this paper
• Food allergy: History, definitions and treatment approaches

  2022cites this paper
• Immunotherapies in the treatment of immunoglobulin E‑mediated allergy: Challenges and scope for innovation (Review).

  2022cites this paper
• Effects of exercise and sleep deprivation on reaction severity during oral peanut challenge: a randomised controlled trial.

  2022cites this paper
• Peanut-Specific IgG4 and IgA in Saliva are Modulated by Peanut Oral Immunotherapy.

  2022cites this paper
• Kinetics of basophil hyporesponsiveness during short-course peanut OIT.

  2022cites this paper
• Allergen recognition by specific effector Th2 cells enables IL‐2‐dependent activation of regulatory T‐cell responses in humans

  2022cites this paper
• Oral Immunotherapy in Food Allergy: A Critical Pediatric Perspective

  2022cites this paper
• Thioredoxin-1: A Promising Target for the Treatment of Allergic Diseases

  2022cites this paper
• Long-term outcomes of oral immunotherapy for anaphylactic egg allergy in children

  2022cites this paper
• Insights into Microbiome and Metabolic Signatures of Children Undergoing Peanut Oral Immunotherapy

  2022cites this paper
• Transcriptional changes in dendritic cells underlying allergen specific induced tolerance in a mouse model

  2022cites this paper
• Maximum Dose Food Challenges Reveal Transient Sustained Unresponsiveness in Peanut Oral Immunotherapy (POIMD study).

  2021cites this paper
• Allergen-Specific IgE and IgG4 as Biomarkers for Immunologic Changes during Subcutaneous Allergen Immunotherapy

  2021cites this paper